Video
REVERSE Type 2 Diabetes in 5 Easy Steps (Yes You Can!)Type diabetes weight management -
Have regular health checks. The diabetes annual cycle of care is a checklist for reviewing your diabetes management and general health each year. Looking after your diabetes is important for your long-term health. If your diabetes is well managed and you take care of your general health, you can reduce the risk of diabetes-related complications.
The glycemic index GI is one tool that can help you choose which carb foods to eat. The GI ranks how quickly or slowly carb foods affect blood glucose levels. For people with type 2 diabetes, being overweight can make it harder to manage blood glucose levels.
For a kg person this would mean losing 5—10kg. It is not just your weight on a scale—it is also the size of your waist. Health professionals recommend a waist circumference of:. The relationship between waist circumference and body fat differs with age and your ethnic background.
Talk to your doctor for advice on recommended measurements. The best way to improve your health is to make small, sustainable changes to your eating behaviour and physical activity. Your diabetes health care team can provide more personalised advice that can make losing weight much easier and sustainable.
Learn to manage your diabetes confidently with diabetes programs , available face-to-face and online. Register for a diabetes program.
This 8-week online program will help you on your journey to a healthier and more active life. Similar to liraglutide 3.
has been shown to provide weight-reduction benefits in obese people with or without prediabetes After 24 weeks, the placebo-subtracted difference in percentage weight reduction was —3.
GLP-1R agonists for oral delivery are also currently under investigation in preclinical and clinical studies Because GLP-1R agonists and basal insulins offer complementary pharmacologic effects on prandial and fasting glycemia 94 , there is growing clinical interest in combinations of these two agents.
The combination of exenatide 10 µg b. with insulin glargine approved in the U. and Europe led to greater reductions in HbA 1c levels, compared with insulin glargine alone —1. Treatment with exenatide and insulin glargine led to a weight decrease of —1. The number of hypoglycemic events between groups did not differ significantly.
Liraglutide with insulin degludec IDegLira —now approved in Europe—is another combination currently being investigated for the treatment of type 2 diabetes.
Initial clinical data show that IDegLira led to greater reductions in HbA 1c —1. IDegLira also provided a modest weight loss of —0. IDegLira also resulted in significantly fewer hypoglycemic episodes than insulin degludec.
A combination of insulin glargine with lixisenatide has also been investigated The addition of lixisenatide to insulin glargine produced greater reductions in HbA 1c —0.
placebo, —3. The addition of lixisenatide also had a favorable effect on body weight difference vs. placebo —0. Nausea, vomiting, and symptomatic hypoglycemia were more commonly reported with lixisenatide than with insulin glargine alone.
Given the role of leptin and amylin in controlling food intake and energy expenditure and the role of incretins GLP-1 in glucose and weight control 97 , 98 , that many of the therapies in preclinical development involve these different hormones is no surprise.
Therapies that are currently being studied are included in Table 5. Because results with recombinant human leptin or metreleptin human leptin analog have been disappointing in reducing HbA 1c levels and weight for obese patients with type 2 diabetes 97 , approaches are now focused on leptin-related synthetic peptides, such as leptin receptor antagonists or leptin-related synthetic peptide analogs or mimetics, and leptin combination therapies Initial preclinical and clinical data suggest that leptin and amylin—two hormones involved in the control of satiety—have additive effects However, a subsequent trial was recently halted due to safety concerns Responsiveness to leptin is associated with decreased food intake, improved glucose tolerance and insulin sensitivity, and with decreased triglycerides and lower plasma cholesterol concentrations.
These results suggest that the pharmacology of leptin in combination with other agents, such as GLP-1R agonists and amylin analogs, warrants additional study as a potential antihyperglycemic therapy that is associated with weight loss. Another potential therapy is the combination of amylin analogs and GLP-1R agonists.
Because both agents can slow gastric emptying, it is possible that these two agents combined may have synergistic effects, but the gastrointestinal tolerance should be evaluated. Another incretin pathway compound in early-stage development is a peptide that acts as an agonist at both the GLP-1 and GIP receptors A preclinical study indicates that this dual agonist has the potential to enhance the antihyperglycemic and antiobesity effects observed with monoagonism because it affects adiposity-induced insulin resistance and pancreatic insulin deficiency.
A recent study in rodents found that a new monomeric peptide triagonist, simultaneously acting at three key metabolically related peptide hormone receptors GLP-1, GIP, glucagon , provided additional glucose control and weight-reducing benefits over dual coagonism Extensive clinical investigation into the efficacy and safety of coagonist therapy for the treatment of patients with obesity and type 2 diabetes is now required.
Owing to the complex pathophysiology of diabetes, additional therapeutic targets are under investigation as potential agents for glycemic control, many in combination with GLP-1R agonists PYY is an incretin hormone that also has a role in satiety The associated hypothesis is that PYY may further enhance the glucose-lowering and weight-reducing effects of GLP-1R agonists.
Fibroblast growth factor 21 has broad metabolic effects, including enhancing insulin sensitivity, decreasing triglyceride concentrations, and inducing weight loss, and this activity acts additively with GLP-1 , Another agent under clinical investigation as an antiobesity agent is beloranib, a fumagillin-class methionine aminopeptidase-2 inhibitor that has recently completed phase 2 trials Further research with all of these targets is required to determine their suitability as antihyperglycemic agents.
Although lifestyle interventions aimed at prompting weight loss are important in the management of type 2 diabetes and the benefits of weight reduction are irrefutable, most patients remain overweight or obese.
A shift in the approach to weight management in people with type 2 diabetes is clearly needed. Recent approvals of therapies that provide both glycemic control and weight reduction, and the healthy pipeline of antiobesity medications, bode well for a wider choice in the future, with some agents targeting the central nervous system to reduce food intake and others targeting the hormonal pathways involved in weight regulation and glucose homeostasis.
The emergence of a range of pharmacotherapies with varying modes of action, coupled with ongoing improvements in our knowledge of the physiology of appetite and energy homeostasis, provides the prospect of a rational combination therapy that is both effective and tolerable. The authors are grateful to Dr.
Jennifer Chang of AXON Communications for writing assistance in the development of the manuscript. received grant support from National Research Funds, Belgium, and also received grant support for hepatic research from the European Union consortium Hepadip and Resolve consortia.
Duality of Interest. Writing assistance for the manuscript was funded by Novo Nordisk. Novo Nordisk was also provided with the opportunity to perform a medical accuracy review. also received an unrestricted research grant from Novo Nordisk and Novartis. No other potential conflicts of interest relevant to this article were reported.
Author Contributions. and A. conceived and designed the manuscript, analyzed and interpreted the data, drafted and revised the paper, and approved the final version for publication. Sign In or Create an Account. Search Dropdown Menu.
header search search input Search input auto suggest. filter your search All Content All Journals Diabetes Care. Advanced Search. User Tools Dropdown. Sign In. Skip Nav Destination Close navigation menu Article navigation. Volume 38, Issue 6. Previous Article Next Article. Weight Gain With Conventional Therapies.
Antidiabetes Therapies With Weight-Loss Potential. Antiobesity Pharmacotherapies. Future Prospects in Clinical Development. Future Prospects in Preclinical Development. Potential Therapeutic Targets. Article Information. Article Navigation. Review May 12 Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment Luc Van Gaal ; Luc Van Gaal.
Corresponding author: Luc Van Gaal, luc. gaal uza. This Site. Google Scholar. André Scheen André Scheen. Diabetes Care ;38 6 — Article history Received:. Connected Content. A reference has been published: In This Issue of Diabetes Care. Get Permissions. toolbar search Search Dropdown Menu. toolbar search search input Search input auto suggest.
Table 1 Antidiabetes therapies associated with weight gain. Drug class. Mechanism of action. How mechanism of action leads to weight gain. View Large.
Baseline patient characteristic predictive of weight gain. Table 3 Antidiabetes therapies that are weight neutral or have weight-loss potential. Table 4 Antiobesity therapies currently approved for chronic weight management.
How mechanism of action leads to weight loss. Table 5 Future prospects. Van Gaal. Search ADS. Obesity and overweight. Fact sheet No. Geneva, Switzerland: World Health Organization International. Accessed 2 Jan The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis.
Management of hyperglycemia in type 2 diabetes, a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.
Impact of intensive lifestyle intervention on depression and health-related quality of life in type 2 diabetes: the Look AHEAD Trial.
A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study.
UK Prospective Diabetes Study UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS Determinants of weight gain in the action to control cardiovascular risk in diabetes trial.
Characterizing and understanding body weight patterns in patients treated with pregabalin. Diet and exercise intervention in a general population—mediators of participation and adherence: the Inter99 study.
The DCCT Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. de Luis. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects.
Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. van Dieren. Weight changes and their predictors amongst 11 patients with type 2 diabetes in the ADVANCE trial.
Insulin-associated weight gain in diabetes—causes, effects and coping strategies. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.
Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Hypoglycemia activates orexin neurons and selectively increases hypothalamic orexin-B levels: responses inhibited by feeding and possibly mediated by the nucleus of the solitary tract.
Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. Evidence for the key role of the adipocyte cGMP-inhibited cAMP phosphodiesterase in the antilipolytic action of insulin.
Causes of weight gain during insulin therapy with and without metformin in patients with type II diabetes mellitus. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. Sleep loss can hurt diabetes management in other ways, too. According to the Harvard T. Chan School of Public Health , not sleeping well can zap the motivation to exercise and increase hunger because of hormone disruption; and poor diet and lack of exercise further exacerbate problems with blood sugar control, according to the Mayo Clinic.
The study authors noted that mobility-related issues increase as the level of obesity and physical inactivity increases. People with diabetes also often have bone and joint issues, which can limit activity, whether because of nerve damage, obesity, or arterial disease, says the Mayo Clinic.
The good news is that losing weight will likely make day-to-day activities easier and help keep mobility-related issues at bay. RELATED: 6 Great Exercises for People With Diabetes. Rinker sees it time and again: When people lose weight through a healthy diet and exercise, their energy level goes up and their mood improves.
According to the CDC , losing weight and keeping it off leads to improvements in self-confidence, too. This boost may give people motivation to better manage their diabetes and continue their healthy habits.
But what about for people who have already been diagnosed? Turns out, slimming down may help them, too, and change the course of the disease. One study found that 40 percent of study participants who lost about 33 pounds and maintained that weight loss for six months were able to send the condition into remission.
RELATED: 8 Steps for Weight Loss Success if You Have Type 2 Diabetes. In general, Rinker recommends choosing lifestyle changes you can sustain rather than relying on fad diets for weight loss and weight management. For example, the ADA suggests starting with the pillars of healthy eating: adding more fruits and vegetables to your diet, as well as lean meats and plant-based protein , and limiting processed foods and added sugar.
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy.
We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Health Conditions A-Z. Best Oils for Skin Complementary Approaches Emotional Wellness Fitness and Exercise Healthy Skin Online Therapy Reiki Healing Resilience Sleep Sexual Health Self Care Yoga Poses See All.
Atkins Diet DASH Diet Golo Diet Green Tea Healthy Recipes Intermittent Fasting Intuitive Eating Jackfruit Ketogenic Diet Low-Carb Diet Mediterranean Diet MIND Diet Paleo Diet Plant-Based Diet See All. Consumer's Guides: Understand Your Treatments Albuterol Inhalation Ventolin Amoxicillin Amoxil Azithromycin Zithromax CoQ10 Coenzyme Q Ibuprofen Advil Levothyroxine Synthroid Lexapro Escitalopram Lipitor Atorvastatin Lisinopril Zestril Norvasc Amlodipine Prilosec Omeprazole Vitamin D3 Xanax Alprazolam Zoloft Sertraline Drug Reviews See All.
Health Tools. Body Type Quiz Find a Doctor - EverydayHealth Care Hydration Calculator Menopause Age Calculator Symptom Checker Weight Loss Calculator.
See All. DailyOM Courses. About DailyOM Most Popular Courses New Releases Trending Courses See All. Type 2 Diabetes. By Moira Lawler. Medically Reviewed. Sandy Bassin, MD of American College of Lifestyle Medicine. Editorial Sources and Fact-Checking.
Resources Diabetes and Your Heart. Centers for Disease Control and Prevention. June 20, Van Gaal L, Scheen A. Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment.
Diabetes Care. June 1, Insulin Resistance and Prediabetes.
Luc Van GaalAndré Scheen; Weight Management in Type diabetes weight management mnagement Diabetes: Current managemdnt Emerging Approaches to Treatment. Diabetes Care 1 June ; 38 diabets : — Diabetes is managment growing global health concern, as is obesity. Citrus oil for refreshing scent and obesity diabetex intrinsically linked: obesity increases the risk of diabetes and also contributes to disease progression and cardiovascular disease. Although the benefits of weight loss in the prevention of diabetes and as a critical component of managing the condition are well established, weight reduction remains challenging for individuals with type 2 diabetes due to a host of metabolic and psychological factors. For many patients, lifestyle intervention is not enough to achieve weight loss, and alternative options, such as pharmacotherapy, need to be considered.
0 thoughts on “Type diabetes weight management”